Drug
Part A Cr845 KG
Part A Cr845 KG: highest development phase Phase 2, developed by Cara Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Cara Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Part A: CR845 0.5 mcg/kg NCT02229929 | Phase 2 | Pruritus |
Latest
No recent events.
Follow Part A Cr845 KG on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.